您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Prostaglandin D2-d9
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Prostaglandin D2-d9
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Prostaglandin D2-d9图片
规格:98%
分子量:361.5
包装与价格:
包装价格(元)
25ug电议
50ug电议
100ug电议

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx23330
CAS:N/A
分子式:C20H23D9O5
分子量:361.5
溶解度:DMF: 100 mg/ml,DMSO: 50 mg/ml,Ethanol: 75 mg/ml,PBS (pH 7.2): 5 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Prostaglandin D2-d9(PGD2-d9) contains nine deuterium atoms at the 17, 17', 18, 18', 19, 19', 20, 20, and 20 positions. It is intended for use as an internal standard for the quantification of PGD2by GC-or LC-mass spectrometry. PGD2is the major eicosanoid product of mast cells and is released in large quantities during allergic and asthmatic anaphylaxis.1Mastocytosis patients produce excessive amounts of PGD2, which causes vasodilation, flushing, hypotension, and syncopal episodes.1PGD2is also produced in the brainviaan alternative pathway involving a soluble, secreted PGD-synthase also known as β-trace.2,3In the brain, PGD2produces normal physiological sleep and lowering of body temperature.2,3Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle.4PGD2inhibits human ovarian tumor cell proliferation with an IC50value of 6.8 µM.5


1.Roberts, L.J., II, and Sweetman, B.J.Metabolic fate of endogenously synthesized prostaglandin D2 in a human female with mastocytosisProstaglandins30(3)383-400(1985) 2.Hayaishi, O.Sleep-wake regulation by prostaglandins D2 and E2J. Biol. Chem.263(29)14593-14596(1988) 3.Onoe, H., Ueno, R., Fujita, I., et al.Prostaglandin D2, a cerebral sleep-inducing substance in monkeysProc. Natl. Acad. Sci. U.S.A.85(11)4082-4086(1988) 4.Giles, H., and Leff, P.The biology and pharmacology of PGD2Prostaglandins35(2)277-300(1988) 5.Kikuchi, Y., Kita, T., Hirata, J., et al.Preclinical studies of antitumor prostaglandins by using human ovarian cancer cellsCancer Metastasis Rev.13(3-4)309-315(1994)